Acoziborole,1266084-51-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Acoziborole

CAS No. : 1266084-51-8

MCE 国际站：Acoziborole

产品活性：Acoziborole (SCYX-7158) 是一种安全有效的抗原虫剂，可用于人类非洲锥虫病 (HAT) 的研究。作用于 T. b. brucei S427 菌株，MIC 值为 0.6 µg/mL。

研究领域：Anti-infection

作用靶点：Parasite

In Vitro: Acoziborole is active in vitro against relevant strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense.In whole cell assays, Acoziborole exhibits potent activity against representative T. b. brucei, T. b. rhodesiense and T. b. gambiense strains. IC₅₀ values for Acoziborole are approximately 0.07 µg/mL to 0.37 µg/mL following incubation of the parasite strains with Acoziborole for 72 h. In the T. b. brucei S427 strain, the MIC value for Acoziborole is 0.6 µg/mL, approximately two times the IC₅₀ measured for this strain. In contrast to the potent activity of Acoziborole against trypanosomes, no significant inhibition of cell proliferation is observed in an in vitro mammalian cell (L929 mouse cell line) assay at drug concentrations up to 50 µg/mL. The potential for Acoziborole to inhibit cytochrome P450 (CYP) enzymes is evaluated using P450-Glo assays for the human isoforms CYP3A4, CYP1A2, CYP2C19, CYP2C9 and CYP2D6. The IC₅₀ values for Acoziborole in these assays are all above 10 µM.

In Vivo: In uninfected mice, 4.3 mg/kg intravenous dose of Acoziborole show an apparent elimination half-life (t_1/2) of 26.6 h; systemic clearance (CL) of 0.089 L/h/kg; a volume of distribution (Vd_ss) of 1.69 L/kg and area under the concentration-time curve (AUC_{0-24 h}) of 48 h•μg/mL. Following an oral dose of 13.4 mg/kg, which corresponds to the lowest efficacious dose in the murine stage 2 HAT model, Acoziborole is rapidly absorbed, as a C_max of 6.96 µg/mL is achieved in plasma at 6 h after dose, with an oral clearance (Cl/F) value of 0.163 L/h/kg, an AUC_{0-24 h} of 82 h•μg/mL and absolute oral bioavailability of 55%. After a 26 mg/kg oral dose, which corresponds to the dose giving a 100% cure rate in the murine stage 2 HAT model, C_max increases to 9.8 µg/mL and the AUC_{0-24 h} is 113 h•μg/mL. In uninfected rats, following oral administration of Acoziborole at a nominal dose of 25 mg/kg (dose affording a 100% cure rate in mice), C_max increases approximately 2 fold more than that in mice (C_max=18.2 µg/mL) and AUC_{0-24 h}, and hence oral clearance, improves approximately 4 fold (AUC_{0-24 h} 291 h•μg/mL and CL/F=0.092 L/kg/h). The time to maximum concentration is similar to that in mice (t_max=8 h). Uninfected male and female cynomolgus monkeys are treated with Acoziborole at 2 mg/kg (IV) on study day 1 and 10 mg/kg (NG) on study day 8. Acoziborole exhibits excellent plasma pharmacokinetics, with CL of 0.022 L/h/kg; Vd_ss of 0.656 L/kg and area under the concentration-time curve 78.8 h•μg/mL, and 94.4 for AUC_{0-24 h} and AUC_0-inf, respectively, following intravenous administration.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Antiparasitic Compound library  |  Rare Diseases Drug Library  |  Chloroquine  |  Hydroxychloroquine sulfate  |  Kaempferol  |  Metronidazole  |  Dihydroartemisinin  |  Ivermectin  |  Niclosamide  |  Artesunate  |  Eflornithine hydrochloride hydrate  |  Suramin sodium salt  |  Artemisinin  |  Halofuginone  |  Quinidine  |  Miransertib  |  RRx-001  |  Doxycycline  |  Nitazoxanide  |  Atovaquone  |  Obatoclax Mesylate  |  Quinacrine dihydrochloride  |  Diminazene aceturate  |  Flufenamic acid  |  Methylene Blue  |  Osthole  |  Mebendazole  |  PK 11195  |  Quinine  |  Dehydrocorydaline

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。